Progyny Reports Strong 2025 Financial Results and Active Share Repurchase Program in Annual 10-K
summarizeSummary
Progyny filed its annual 10-K, confirming strong 2025 financial results with increased revenue and profitability, an expanded gross margin, and significant share repurchases under a new $200 million program.
check_boxKey Events
-
Strong 2025 Financial Performance Confirmed
Progyny reported a 10% increase in revenue to $1.29 billion, a 7.7% rise in net income to $58.5 million, and an 11.7% growth in Adjusted EBITDA to $222.1 million for the fiscal year ended December 31, 2025. Gross margin also expanded by 190 basis points to 23.6%.
-
Active Share Repurchase Program
The company authorized a new $200 million share repurchase program in November 2025. As of the filing date (February 27, 2026), Progyny has already repurchased $159.4 million worth of common stock under this program, with $116.4 million remaining available.
-
Enhanced Financial Flexibility with New Credit Facility
Progyny entered into a $200 million revolving credit facility on July 1, 2025, which remained undrawn as of the filing date, providing additional liquidity and financial flexibility.
-
COO Adopts 10b5-1 Trading Plan
Chief Operating Officer Melissa Cummings adopted a Rule 10b5-1 trading plan on December 19, 2025, to sell up to 24,062 shares of common stock by March 31, 2027. This is a routine, pre-planned sale.
auto_awesomeAnalysis
This 10-K filing confirms Progyny's robust financial performance for fiscal year 2025, building on the preliminary results announced in yesterday's 8-K. The report details significant growth in revenue, net income, and Adjusted EBITDA, alongside an impressive expansion in gross margin. The company's active share repurchase program, with $159.4 million already executed under a new $200 million authorization, signals strong capital return to shareholders and management's confidence in the company's valuation. The establishment of a new $200 million revolving credit facility further enhances financial flexibility. While the core earnings figures were previously disclosed, this comprehensive annual report provides crucial audited details, risk factors, and a deeper understanding of the company's strategic direction and financial health, making it highly important for investors.
At the time of this filing, PGNY was trading at $21.06 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $1.9B. The 52-week trading range was $17.98 to $28.75. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.